Bard buy
This article was originally published in The Gray Sheet
Executive Summary
CR Bard signs $166 mil. agreement March 1 to acquire catheter securement technology firm Venetec International. Bard, with net sales of $1.77 bil. in 2005, estimates the deal will increase 2006 revenue growth by one percentage point over prior expectations, to 10%-11%, or by roughly $18 mil. The deal is expected to close in the second quarter. San Diego-based Venetec makes the StatLock line of molded gripping devices, which provide an alternative to tape or sutures for holding catheters in place. The items are used in catheter insertion kits and trays sold by Bard and other firms. Bard CEO Timothy Ring said the StatLock devices "fit very well strategically" with leading Bard products, including central venous and peripherally inserted central catheters and Foley and dialysis catheters...
You may also be interested in...
Bard secures Venetec
CR Bard announces April 10 that it has completed its $166 mil. acquisition of StatLock securement technology manufacturer Venetec International. Bard has estimated that the move will result in an additional $18 mil. in 2006 revenue (1"The Gray Sheet" March 6, 2006, In Brief)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.